Translational Significance of CDKN2A/B Homozygous Deletion in IDH-Mutant Astrocytoma.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac205
Abstract: Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical… read more here.
Keywords: idh mutant; cdkn2a homozygous; mutant astrocytoma; homozygous deletion ... See more keywords
Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study
Sign Up to like & getrecommendations! Published in 2023 at "Korean Journal of Radiology"
DOI: 10.3348/kjr.2022.0732
Abstract: Objective Cyclin-dependent kinase inhibitor (CDKN)2A/B homozygous deletion is a key molecular marker of isocitrate dehydrogenase (IDH)-mutant astrocytomas in the 2021 World Health Organization. We aimed to investigate whether qualitative and quantitative MRI parameters can predict… read more here.
Keywords: deletion; isocitrate dehydrogenase; homozygous deletion; mutant astrocytomas ... See more keywords